HPV vaccination for MSM: Synthesis of the evidence and recommendations from the Québec Immunization Committee

18Citations
Citations of this article
62Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

ABSTRACT: Diseases associated with the human papilloma virus (HPV) are particularly common among men who have sex with men (MSM). Unlike heterosexual men, MSM do not benefit from the herd protection provided by the vaccination of girls. In this review, we synthesize the available evidence on HPV vaccination for MSM. We also present the recommendations of the Québec Immunization Committee (CIQ) in this regard, which are: to provide targeted vaccination for MSM up to 26 years of age and in-school vaccination of preadolescent boys since this is the best approach to take to have a real impact on the burden related to HPV in the MSM population and to provide direct protection for all men.

Cite

CITATION STYLE

APA

Sauvageau, C., & Dufour-Turbis, C. (2016, June 2). HPV vaccination for MSM: Synthesis of the evidence and recommendations from the Québec Immunization Committee. Human Vaccines and Immunotherapeutics. Taylor and Francis Inc. https://doi.org/10.1080/21645515.2015.1112474

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free